RBC Capital has increased its price target for Biogen Inc. to $227 from $222, maintaining an Outperform rating on the stock, which is currently priced at $193.08. The increase follows a mini-symposium that highlighted the potential of Biogen's pipeline in treating conditions such as kidney disease, Alzheimer’s, and lupus. Analysts noted that the stock has appreciated by 50% over the past year but remains undervalued, with a Fair Value estimated at $259. Key opinion leaders at the symposium expressed strong interest in drugs like litifilimab for cutaneous lupus and dapi-pegol for systemic lupus. In contrast, recent clinical trials for BIIB122, aimed at treating Parkinson's disease, did not meet their endpoints, leading to the discontinuation of its development. Additionally, while the Phase II study of BIIB080 for Alzheimer’s also fell short, other studies, particularly the CELIA study of diranersen, showed promising results, further supporting Biogen's growth potential.